BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17986787)

  • 21. Curcumin is an inhibitor of p300 histone acetylatransferase.
    Marcu MG; Jung YJ; Lee S; Chung EJ; Lee MJ; Trepel J; Neckers L
    Med Chem; 2006 Mar; 2(2):169-74. PubMed ID: 16787365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism.
    Farrajota K; Cheng S; Martel-Pelletier J; Afif H; Pelletier JP; Li X; Ranger P; Fahmi H
    Arthritis Rheum; 2005 Jan; 52(1):94-104. PubMed ID: 15641079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species.
    Kang J; Chen J; Shi Y; Jia J; Zhang Y
    Biochem Pharmacol; 2005 Apr; 69(8):1205-13. PubMed ID: 15794941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
    Rahim R; Strobl JS
    Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor.
    Gaughan L; Logan IR; Cook S; Neal DE; Robson CN
    J Biol Chem; 2002 Jul; 277(29):25904-13. PubMed ID: 11994312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
    Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
    Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ING3 promotes prostate cancer growth by activating the androgen receptor.
    Nabbi A; McClurg UL; Thalappilly S; Almami A; Mobahat M; Bismar TA; Binda O; Riabowol KT
    BMC Med; 2017 May; 15(1):103. PubMed ID: 28511652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
    Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
    J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-4 activates androgen receptor through CBP/p300.
    Lee SO; Chun JY; Nadiminty N; Lou W; Feng S; Gao AC
    Prostate; 2009 Feb; 69(2):126-32. PubMed ID: 18819102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia enhances the expression of prostate-specific antigen by modifying the quantity and catalytic activity of Jumonji C domain-containing histone demethylases.
    Lee HY; Yang EG; Park H
    Carcinogenesis; 2013 Dec; 34(12):2706-15. PubMed ID: 23884959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
    Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
    Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells.
    Miyajima N; Maruyama S; Bohgaki M; Kano S; Shigemura M; Shinohara N; Nonomura K; Hatakeyama S
    Cancer Res; 2008 May; 68(9):3486-94. PubMed ID: 18451177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.
    Zucconi BE; Makofske JL; Meyers DJ; Hwang Y; Wu M; Kuroda MI; Cole PA
    Biochemistry; 2019 Apr; 58(16):2133-2143. PubMed ID: 30924641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth.
    Haery L; Lugo-Picó JG; Henry RA; Andrews AJ; Gilmore TD
    Mol Cancer; 2014 Feb; 13():29. PubMed ID: 24529102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development.
    Lee JH; Yang B; Lindahl AJ; Damaschke N; Boersma MD; Huang W; Corey E; Jarrard DF; Denu JM
    ACS Chem Biol; 2017 Nov; 12(11):2804-2814. PubMed ID: 28949514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6.
    Debes JD; Schmidt LJ; Huang H; Tindall DJ
    Cancer Res; 2002 Oct; 62(20):5632-6. PubMed ID: 12384515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
    Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
    Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells.
    Chung BH; Lee HY; Lee JS; Young CY
    Cancer Lett; 2006 May; 236(2):222-8. PubMed ID: 16029925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitor of CBP Histone Acetyltransferase Downregulates p53 Activation and Facilitates Methylation at Lysine 27 on Histone H3.
    Vincek AS; Patel J; Jaganathan A; Green A; Pierre-Louis V; Arora V; Rehmann J; Mezei M; Zhou MM; Ohlmeyer M; Mujtaba S
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30072621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.
    Yan G; Eller MS; Elm C; Larocca CA; Ryu B; Panova IP; Dancy BM; Bowers EM; Meyers D; Lareau L; Cole PA; Taverna SD; Alani RM
    J Invest Dermatol; 2013 Oct; 133(10):2444-2452. PubMed ID: 23698071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.